Correlation Between Intravascular Platelet Aggregation in Tumors and Hypoxia-Inducible Factor 1 Alpha Expression in Epithelial Ovarian Cancer: Implications for Prognosis and Staging

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2025 Feb 13

PMID 39941717

Authors

Jung Min Ryu

Yoon Young Jeong

Sun-Jae Lee

Youn Seok Choi

Affiliations

Soon will be listed here.

Abstract

Background/objectives: This study aimed to evaluate the association between intravascular platelet aggregation in tumors and ovarian carcinoma prognosis and investigate underlying mechanisms.

Methods: A retrospective analysis was conducted on 144 patients with ovarian carcinoma. Immunohistochemical staining for CD42b, hypoxia-inducible factor-1α (HIF-1α), platelet-derived growth factor (PDGF), and vascular endothelial growth factor (VEGF) was performed using tissue microarrays to assess intravascular platelet aggregation. Staining grades ranged from 1 to 3 for CD42b (platelet aggregation or microthrombus) and 0 to 3 for HIF-1α, PDGF, and VEGF.

Results: Among the patients, 25 (17.4%) had grade 1 (no platelet aggregation), 85 (59.0%) had grade 2 (platelet aggregation), and 34 (23.6%) had grade 3 (microthrombus). The grade of intravascular platelet aggregation in ovarian carcinoma was statistically significantly associated with a poor prognosis ( = 0.037). In addition, in patients with more advanced stages of ovarian cancer, higher levels of intravascular platelet aggregation were observed. Additional analysis revealed a correlation between platelet aggregation and HIF-1α expression (correlation coefficient = 0.226, = 0.006), while PDGF and VEGF showed no significant correlations.

Conclusions: Intravascular platelet aggregation in tumors is associated with advanced stages and poor prognosis in ovarian carcinoma. The results of our study suggest a potential association with hypoxia induced by intravascular platelet aggregation in ovarian carcinoma.

References

Yang H, Zhang H, Yang Y, Wang X, Deng T, Liu R . Hypoxia induced exosomal circRNA promotes metastasis of Colorectal Cancer via targeting GEF-H1/RhoA axis. Theranostics. 2020; 10(18):8211-8226. PMC: 7381736. DOI: 10.7150/thno.44419. View

Clemetson K, Clemetson J . Platelet GPIb-V-IX complex. Structure, function, physiology, and pathology. Semin Thromb Hemost. 1995; 21(2):130-6. DOI: 10.1055/s-2007-1000387. View

Honn K, Tang D, Chen Y . Platelets and cancer metastasis: more than an epiphenomenon. Semin Thromb Hemost. 1992; 18(4):392-415. DOI: 10.1055/s-2007-1002578. View

Zhang S, Yao L, Wang W, Xu J, Xu H, Jin W . Tumor-Infiltrating Platelets Predict Postsurgical Survival in Patients with Pancreatic Ductal Adenocarcinoma. Ann Surg Oncol. 2018; 25(13):3984-3993. DOI: 10.1245/s10434-018-6727-8. View

Jurasz P, Alonso-Escolano D, Radomski M . Platelet--cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation. Br J Pharmacol. 2004; 143(7):819-26. PMC: 1575943. DOI: 10.1038/sj.bjp.0706013. View

Zeimet A, Marth C, Muller-Holzner E, Daxenbichler G, Dapunt O . Significance of thrombocytosis in patients with epithelial ovarian cancer. Am J Obstet Gynecol. 1994; 170(2):549-54. DOI: 10.1016/s0002-9378(94)70225-x. View

Oncul S, Cho M . Interactions between Platelets and Tumor Microenvironment Components in Ovarian Cancer and Their Implications for Treatment and Clinical Outcomes. Cancers (Basel). 2023; 15(4). PMC: 9953912. DOI: 10.3390/cancers15041282. View

Rafii S, Shapiro F, Pettengell R, Ferris B, Nachman R, Moore M . Human bone marrow microvascular endothelial cells support long-term proliferation and differentiation of myeloid and megakaryocytic progenitors. Blood. 1995; 86(9):3353-63. View

Wang J, Zhang M, Zhou T, Zhao S, Su Z, Liu X . Role of platelet infiltration as independent prognostic marker for gastric adenocarcinomas. J Clin Lab Anal. 2020; 34(8):e23320. PMC: 7439343. DOI: 10.1002/jcla.23320. View

10.

Rickles F, Falanga A . Molecular basis for the relationship between thrombosis and cancer. Thromb Res. 2001; 102(6):V215-24. DOI: 10.1016/s0049-3848(01)00285-7. View

11.

Correia A, Bissell M . The tumor microenvironment is a dominant force in multidrug resistance. Drug Resist Updat. 2012; 15(1-2):39-49. PMC: 3658318. DOI: 10.1016/j.drup.2012.01.006. View

12.

Pujade-Lauraine E, Ledermann J, Selle F, Gebski V, Penson R, Oza A . Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017; 18(9):1274-1284. DOI: 10.1016/S1470-2045(17)30469-2. View

13.

Semenza G . Cancer-stromal cell interactions mediated by hypoxia-inducible factors promote angiogenesis, lymphangiogenesis, and metastasis. Oncogene. 2012; 32(35):4057-63. PMC: 4415159. DOI: 10.1038/onc.2012.578. View

14.

Meikle C, Kelly C, Garg P, Wuescher L, Ali R, Worth R . Cancer and Thrombosis: The Platelet Perspective. Front Cell Dev Biol. 2017; 4:147. PMC: 5214375. DOI: 10.3389/fcell.2016.00147. View

15.

Ikeda M, Furukawa H, Imamura H, Shimizu J, Ishida H, Masutani S . Poor prognosis associated with thrombocytosis in patients with gastric cancer. Ann Surg Oncol. 2002; 9(3):287-91. DOI: 10.1007/BF02573067. View

16.

Xu S, Xu H, Wang W, Li S, Li H, Li T . Tumor-infiltrating platelets predict postoperative recurrence and survival in resectable pancreatic neuroendocrine tumor. World J Gastroenterol. 2019; 25(41):6248-6257. PMC: 6848018. DOI: 10.3748/wjg.v25.i41.6248. View

17.

Davis R, Theologides A, Kennedy B . Comparative studies of blood coagulation and platelet aggregation in patients with cancer and nonmalignant diseases. Ann Intern Med. 1969; 71(1):67-80. DOI: 10.7326/0003-4819-71-1-67. View

18.

Sasaki K, Kawai K, Tsuno N, Sunami E, Kitayama J . Impact of preoperative thrombocytosis on the survival of patients with primary colorectal cancer. World J Surg. 2011; 36(1):192-200. DOI: 10.1007/s00268-011-1329-7. View

19.

Mirza M, Monk B, Herrstedt J, Oza A, Mahner S, Redondo A . Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016; 375(22):2154-2164. DOI: 10.1056/NEJMoa1611310. View

20.

Taucher S, Salat A, Gnant M, Kwasny W, Mlineritsch B, Menzel R . Impact of pretreatment thrombocytosis on survival in primary breast cancer. Thromb Haemost. 2003; 89(6):1098-106. View